Alnylam Pharmace. Stock
Alnylam Pharmace. Stock
There is an upward development for Alnylam Pharmace. compared to yesterday, with an increase of €3.00 (1.080%).
With 52 Buy predictions and not a single Sell prediction Alnylam Pharmace. is an absolute favorite of our community.
With a target price of 422 € there is a hugely positive potential of 52.18% for Alnylam Pharmace. compared to the current price of 277.3 €.
Our community identified positive and negative aspects for Alnylam Pharmace. stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Alnylam Pharmace. stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Pros and Cons of Alnylam Pharmace. in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
B****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Alnylam Pharmace. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alnylam Pharmace. | 1.080% | -0.503% | 4.291% | 24.820% | -18.211% | 55.412% | 128.970% |
| United Therapeutics | -0.150% | 1.842% | 17.061% | 64.600% | 8.706% | 124.071% | 231.786% |
| Iovance Biotherapeutics Inc. | -4.820% | -23.598% | 61.433% | 7.195% | 48.229% | -45.361% | -87.411% |
| Ligand Pharmaceuticals | -1.660% | 1.667% | 16.561% | 86.735% | 10.241% | 191.773% | 34.213% |
Comments
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $510.00 price target on the stock.
Show more
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target raised by analysts at Canaccord Genuity Group Inc. from $415.00 to $429.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by analysts at Needham & Company LLC from $529.00 to $510.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ALNY provided by MarketBeat